Treatment of disseminated forms of osteogenic sarcoma

 

(57) Abstract:

The invention relates to medicine, namely to Oncology, and can be used in the treatment of osteogenic disseminated sarcoma. Proposed patient prior to the introduction of chemotherapeutic agents to take a biopsy of a tumor, to determine in the cytosolic fraction of receptors for 5 [1,2,3,4,5,6,-3H] dihydrotestosterone and receptors as drug use flucinom. Mainly flucinom injected at a dose of 250 mg 3 times a day for 1.5-2 years the infusion of chemotherapeutic agents. 2 C.p. f-crystals, 2 tab.

The invention relates to medicine, namely to methods for treating disseminated forms of osteogenic sarcoma.

Annually in Russia, the diagnosis is established in 2000 patients. The majority of patients does not exceed 35 years. Predominantly young age of patients, early hematogenous metastasis, morbidity and mortality within 1 year. the life expectancy of such patients is on average 6-8 months, despite the use of all modern methods of treatment, make this one of the actual problem.

Currently, the treatment of this disease proway therapy, however, all of them are not effective.

There is a method of treatment of disseminated forms of osteogenic sarcoma, which consists in conducting 6-9 cycles of chemotherapy, including, for example, adriamycin, cisplatin, cyclophosphamide, in combination with radiation therapy or surgery (N.N. Trapeznikov and other Tumors of bone. - M.: Medicine, 1986, S. 269-275).

The disadvantage of this method is the high mortality, poor quality of life.

The present invention is to provide a method for treatment of disseminated forms of osteogenic sarcoma, which can increase life expectancy by stabilizing the process, complete or partial regression of the primary tumor and metastases, to improve the quality of life.

This object is achieved in that in the method of treatment of disseminated forms of osteogenic sarcoma by administering drugs that suppress tumor growth, in combination with radiation therapy or surgery in the patient prior to administration of drugs take a biopsy of a tumor is determined in the cytosolic fraction of receptors for 5 [1,2,3,4,5,6,-3H] dihydrotestosterone and receptors as drug cf the ptx2">

The patient in biopsy material from the tumor determine the receptors 5 [1,2,3,4,5,6, -3H] dihydrotestosterone, conduct intra-arterial chemotherapy and depending on the sensitivity, and the size of the tumor spend radiation therapy or perform an operation. In the presence of receptors for 5 [1,2,3,4,5,6,-3H] dihydrotestosterone sick assign flucinom according to the proposed scheme, and in their absence, continue the introduction of chemotherapeutic drugs. The results are presented in tables 1 and 2.

Examples of specific implementation method.

Example 1. Patient K., age 16, history 98/17571. The diagnosis of osteogenic sarcoma of the distal right femur confirmed based on morphological studies. The androgen receptor 169 fmol/mg total protein. Started intraarterial chemotherapy cisplatino 250 mg. Just spent 6 courses with an interval of 4 weeks each. Operative treatment: resection of the distal right femur with the knee joint. In further conducted 4 adjuvant chemotherapy cisplatino 180 mg, adriamycin 70 mg, cyclophosphamide 600 mg for each course with an interval of 4 weeks.). Assigned therapy flucinom 250 mg 3 times a day. Achieved complete regression of metastatic tumors. The observation period is 7 months. Monitoring continues.

Example 2. Patient T., aged 44, history 98/6336. The diagnosis of osteogenic sarcoma 6 ribs on the left confirmed based on histological studies. Receptors androgen - 162 fmol/mg total protein. Performed resection of the ribs. From chemotherapy refused. Recurrence of disease after 5 months. She started chemotherapy cisplatino 180 mg, 80 mg adriamycin, cyclophosphamide 600 mg were 5 courses. Revealed multiple metastases in the ribs, the left lung, the lymph nodes in the neck. Scheduled flucinom 250 mg 3 times a day. Achieved reduction of metastases in the bones by 25%-50%. Pain stopped completely. Stabilization of metastasis in the left lung. Complete regression of metastases in the lymph nodes of the neck. Follow-up period of 18 months. Monitoring continues.

Example 3. Patient D., aged 35, history 98/6086. The diagnosis of osteogenic sarcoma of the right femur confirmed based on morphological studies. The patient revealed multiple metastases in the lungs. The androgen receptor 59 fmol/mg total protein. Started in the hol held radiotherapy to 60 Gy. Adjuvant chemotherapy is continued by cisplatino 180 mg and adriamycin 70 mg Undertaken 3 courses. The progression of lung metastases. Scheduled flucinom 250 mg 3 times a day longer. Marked stabilization of lung metastases in 14 months. Observation continues

Example 4. Patient P., 17 years old, medical history 99/5501. The diagnosis of osteogenic sarcoma of the proximal right tibia confirmed based on histological studies. The androgen receptor 162 fmol/mg total protein. Started intraarterial chemotherapy with adriamycin 150 mg within 72 hours. Received 2 courses. Revealed multiple metastases in the lungs and bones. On primary tumor radiation therapy up to 60 Gy. Chemotherapy was continued by adriamycin 70 mg and cisplatino 150 mg Undertaken 3 courses. The progression of metastases in the lungs and bones. The expressed painful syndrome. Assigned therapy flucinom 250 mg 3 times as long. Pain stopped completely. Metastases in the bones decreased in size by more than 50%. Achieved stabilization of lung metastases within 7 months. Monitoring continues.

The technical result.

Thus, the proposed Sonia mortality due process stabilization and regression of the tumor as a primary focus, and metastases.

1. Treatment of disseminated forms of osteogenic sarcoma by administering drugs that suppress tumor growth in combination with radiation therapy or surgery, wherein the patient before administering drugs take a biopsy of a tumor is determined in the cytosolic fraction of receptors for 5[1,2,3,4,5,6,-3H] dihydrotestosterone and receptors as drug use flucinom.

2. The method according to p. 1, characterized in that flucinom enter predominantly at a dose of 250 mg 3 times a day for 1.5-2 years.

3. The method according to p. 1, characterized in that flucinom use the infusion of chemotherapeutic agents.

 

Same patents:

The invention relates to coordination compounds of metals exhibiting cytotoxic activity and can be used in medicine and veterinary medicine for the purpose of chemotherapy

The invention relates to novel analogues of camptothecin formula (1), where R1- alkyl, alkylen, quinil, R2, R3, R4- H, halogen, halogenated, alkyl, alkenyl, -(CH2)mOR6, unsubstituted or substituted phenyl or phenylalkyl or R3and R4form together a chain with 3 or 4 members in which there may be elements of CH, CH2, O, N, or NR9, R3-H, halogen, halogenated, alkyl, alkoxy, substituted or unsubstituted phenyl or phenylalkyl, R6-H, alkyl, R9-H, alkyl, R18and R19-H, halogen, alkyl, alkoxy, hydroxy, R20-H, halogen, Rp-H, -C(O)-A-NR22R23where A - alkalinity radical, R22and R23- H, alkyl, m = 0 to 6 if Rp-H, R3and R4together form a chain with 3 or 4 members

The invention relates to medicine, in particular to Oncology, and concerns the use of some selective inhibitors of cyclooxygenase-2 for the treatment and prevention of cachexia

Chemical compounds // 2189251
The invention relates to medicine, in particular Oncology
The invention relates to medicine, namely to gynecology, and can be used for the treatment of patients with common process of ovarian cancer with extensive metastasis

The invention relates to medicine, in particular to Oncology, and relates to a method of treatment multilatina resistant tumors in mammals comprising the administration to a patient in need of such treatment, an effective amount of inhibitory multilocational resistance antimultiplicative resistant derivative lamellarin

The invention relates to new salts of 5,5'-aileenpearlpiyali and 5,5'-arylidene(2-thiobarbiturate) acid and 5,5' - arylidene(2-thiobarbiturate) acids of General formula I having antimicrobial, antiviral, immunomodulatory and antitumor activity

The invention relates to 3-dimethylthiophenol derivative of General formula (I) in which R can be a

< / BR>
NON2-SNON-CH2-, H2NCH2CHOHCH2-, HOOCCH2-, OH-CH2-CHCl-CH2-, to methods for their preparation, to contain their pharmaceutical compositions and to their use in the field of rheumatology and orthopedics to get drugs with muscle relaxant and anti-inflammatory activities

The invention relates to a stable pharmaceutical composition containing a combination of drugs, such as amlodipine, besylate, calcium channel blocker class of dihydropyridines and atenolol,-adrenergic-derived class benzanilide that are used in some cardiovascular diseases, such as angina, myocardial infarction, hypertension

The invention relates to an inhibitor of the activity of esterified cholesterol transport protein (HETB), comprising as active ingredient a compound represented by the formula (I), where R is a straight or branched alkyl group; a lower halogenating group; substituted or unsubstituted cycloalkyl group; substituted or unsubstituted cycloalkylcarbonyl group; substituted or unsubstituted aryl group, or substituted or unsubstituted heterocyclic group, X1X2X3and X4may be the same or different and each represents a hydrogen atom, halogen atom, lower alkyl group, lower halogenating group; a lower alkoxygroup; a cyano; a nitro-group; Y represents-CO -, and Z represents a hydrogen atom or mercaptohexanol group, or its pharmaceutically acceptable salt, or hydrate, or MES

The invention relates to pharmacology and for the treatment of burn wounds

The invention relates to the field of medicine and the pharmaceutical industry and relates to intranasal antiseptic for the treatment of diseases of the nasopharynx

The invention relates to medicine, and is intended for the prevention of delayed emesis

The invention relates to the derivatives of colchicine formula (I), where R denotes methoxy or methylthiourea; R1means a linear or branched C1- C6alkyl, provided that when R is methoxy, R1cannot be methyl; and compounds of formula II, where R is methylthio; R1means a linear or branched C1- C6-alkyl

The invention relates to new derivatives of phenoxyethylamine General formula (I) where the substituents have the values with high affinity to 5-HT1Areceptor
The invention relates to medicine, in particular to the drug for inhalation, representing a dry powder composition comprising formoterol and substance-media, which are in fine form, and the drug has a loose bulk density of 0.28 - 0,38 g/ml and is useful in the treatment of respiratory disorders, and also relates to a method for obtaining a composition and to a method of treatment of a patient suffering from a respiratory disorder

The invention relates to new compounds of formula I, where R1- H, alkyl, aryl, R2- alkyl, R3- H, halogen, the nitro-group, R4- H, alkyl, Z is alkyl, W is alkyl, alkoxy, substituted aryl, substituted heteroaryl, where the heteroatoms may be O, N, S, and substituted amino group and substituted oxygraph, X - substituted aryl or substituted heteroaryl, where the heteroatoms may be O, N, S

FIELD: organic chemistry, pharmacology.

SUBSTANCE: invention relates to compounds of formula I ,

where R(1), R(2), R(3), R(4), R(5), R(6), R(7), R(8), R(30), and R(31) are disclosed in claims. Compound of present invention are particularly useful as new antiarrythmia bioactive substances, in particular for treatment and prophylaxis of atrial arrhythmia (e.g., atrial fibrillation or auricular flutter).

EFFECT: higher efficiency.

13 cl, 18 ex, 1 tbl

Up!